Collaborating on a vaccine for cancer

The company is developing a novel cancer vaccine based on a specific antigen and needed the research expertise to help them understand, at a molecular level, how that antigen is expressed in different types of cancer. They turned to Dalhousie postdoctoral fellow Olga Hrytsenko for insight. Olga’s 17 years of molecular biology experience is the “perfect fit” for the project says Marianne Stanford, Director of Research, at Immunovaccine.

Award Winner Interview: SayedMasoud Hashemi Amroabadi

The research led to a 78% reduction in CT image noise which facilitates a corresponding decrease in the patient radiation exposure required for high quality CT images, saving patients from the potentially harmful effects of X-ray dose radiation.  Below is an exclusive interview with Mr. Hashemi, who won the Mitacs Award for Novelty in Application, as presented by the Honourable Gail Shea, Minister of National Revenue at the 2nd Annual Mitacs Awards Reception, held November 28th in Ottawa.

Award Winner Interview: Joanna Triscott

Because of this research, BC Children’s Hospital can how examine all new cases of pediatric brain tumors throughout the entirety of Western Canada with precision and accuracy – thus reducing the (often excessive) intensity of treatment for children with cancer while still effectively treating the disease.  Below is an exclusive interview with Ms.

Award Winner Interview: Oualid Haddad

The research led to the completion of a motorized incubator device that now enables researchers to observe live cells for days at a time as they are stretched under the microscope.  His work may help to cure a devastating skin blistering disease called epidermolysis bullosa simplex.  Below is an exclusive interview with Mr.

AllerGen boosts annual trainee event with Mitacs Step workshop

AllerGen’s 50+ trainees learned how to refresh, build and make the most of their existing networks at the Mitacs Step workshop.

Mitacs Accelerate partnership leads to development of high-tech diabetic insoles

By 2020, it is estimated that diabetes will cost the Canadian healthcare system $16.9 billion a year. In response, Calgary-based Orpyx Medical Technologies is developing a product that is garnering the attention of the diabetes technology community. The SurroSense Rx is a pressure sensitive insole that relays plantar pressure information to a wristwatch, notifying the user when damage is being done to their feet so that behavior can be modified to avoid complications.

A match made in digital philanthropy

The well-informed and critical nature of this response which contributed to the downfall of the Kony campaign is part of a growing trend among would-be philanthropists to scrutinize the practices of charities to whom they might otherwise give. Recognizing such a trend in philanthropy, Calgary-based Dexterity Ventures Inc. saw a need to match donors to deserving charities, launching Place2Give.com as a depository of accessible and transparent information for over 86,000 registered Canadian charities.

Mitacs collaborates with research partners to investigate innovative therapies

Every year, thousands of Canadian children are diagnosed with, or treated for, brain disorders such as Fetal Alcohol Spectrum Disorders (FASD), Autism Spectrum Disorders (ASD) and cerebral palsy. As a national scientific research network, NeuroDevNet has dedicated its mission towards finding the root causes of these disorders. 

Elevating the interplay of art and science

Peter is currently in the final year of his Mitacs Elevate Postdoctoral Fellowship at McMaster University. Supported by his industrial partner, Sentinelle Medical, Inc. (a Hologic company), he is focused on clinical applications of combined MRI and ultrasound for improving diagnosis and treatment of cancer patients.

Mitacs intern gains useful insight into industry

Over the course of his Accelerate internship Zaifman, a postdoctoral fellow at the Chemistry department of the University of British Columbia, partnered with AlCana, a Vancouver biotechnology company developing lipid nanoparticles, which show great potential as a new means for the targeted delivery of therapeutics.

Pages